Latest Breaking News On - Negative metastatic breast - Page 6 : comparemela.com

AstraZeneca: LYNPARZA (olaparib) in Combination with Bevacizumab, and as a Monotherapy, Demonstrates Clinically Meaningful Survival Benefit in 1st-Line Advanced Ovarian Cancer Across Two Phase III Trials

Landmark 5-year follow-up of PAOLA-1 Phase III trial demonstrated LYNPARZA plus bevacizumab meaningfully extended survival with 65.5% of HRD-positive patients surviving 5 years vs. 48.4% treated with

Sao pauloUnited kingdomRhode islandUnited statesIsabelle ray coquardPaul disilvestroJessica mcduellBrendan mcevoyEliav barrSusan galbraithInvestigateurs national des etudes cancers ovariensNational cancer instituteMerck research laboratoriesEuropean network of gynaecological oncological trialEuropean society of medical oncologyResearch association de recherche

Merck (MRK) and AstraZeneca (AZN) Announces LYNPARZA Approved in Japan as Adjuvant Treatment for Patients With BRCA-Mutated, HER2-Negative High Recurrent Risk Breast Cancer

Merck (MRK) and AstraZeneca (AZN) Announces LYNPARZA Approved in Japan as Adjuvant Treatment for Patients With BRCA-Mutated, HER2-Negative High Recurrent Risk Breast Cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesCity ofUnited kingdomDave fredricksonChrissy trankPeter dannenbaumAndrew tuttDamini chokshiMelissa moodyEliav barrKing college londonFrontier science technology research foundationStatement of merck co incBreast international groupMerck co incEuropean union

LYNPARZA® (olaparib) Approved in Japan as Adjuvant Treatment for Patients With BRCA-Mutated, HER2-Negative High Recurrent Risk Breast Cancer

LYNPARZA® (olaparib) Approved in Japan as Adjuvant Treatment for Patients With BRCA-Mutated, HER2-Negative High Recurrent Risk Breast Cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Results From Phase 3 PROpel Trial of LYNPARZA (olaparib) Plus Abiraterone in First-Line Metastatic Castration-Resistant Prostate Cancer Published in NEJM Evidence

21.06.2022 - AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the results from the Phase 3 PROpel trial have been published in NEJM Evidence. Results from the trial showed that LYNPARZA in combination .

United statesNoel clarkeEliav barrCristian massacesiMerck research laboratoriesAmerican society of clinical oncologyUniversity of manchesterData monitoring committeeStatement of merck co incMerck co incExchange commissionEuropean unionSalford royal hospitalsClinical oncologyGenitourinary cancers symposiumAcute myeloid leukemia

Merck To Present Data at 2022 ASCO Annual Meeting Highlighting Promising Pipeline Medicines and Significant Progress in Treating Earlier Stages of Certain Cancers With KEYTRUDA (pembrolizumab)

10.05.2022 - Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that data for six approved medicines and pipeline candidates in more than 25 types of cancer will be presented at the 2022 American Society of Clinical Oncology .

United statesNeoadjuvant pembrolizumabPembrolizumab pembroPembrolizumab monotherapyStatement of merck co incMerck co incExchange commissionOncology investor eventOral presentationExploratory analysisPoster presentationYear follow up of the phaseHealth related quality of lifeImpact of pembrolizumabPlus best supportive careVersus placebo